Insurance coverage for CAR-T cell therapies from Novartis, Gilead get Swiss Govt nod
The health department said the decision covered Novartis's Kymriah and Gilead's Yescarta.
New Delhi: The Swiss government approved on Friday health insurance coverage for CAR-T cell therapies from Novartis and Gilead Sciences, which can cost hundreds of thousands of dollars per patient.
In this form of therapy, patients' white blood cells are genetically modified to attack cancer cells.
The health department said the decision covered Novartis's Kymriah and Gilead's Yescarta.
Read Also: Novartis gets U.S. nod for a long-delayed copycat version of Amgen billion seller Neulasta drug
"The contract between hospitals and the health insurers will be approved until the end of 2020, granting the affected patients immediate access to these therapies," the government said after a cabinet meeting.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd